Celldex Therapeutics Inc. (CLDX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Celldex Therapeutics Inc. (CLDX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

23.00

-1.32 (-5.43%)

At close: Jan 14, 2025, 3:59 PM

22.90

-0.43%

After-hours Jan 14, 2025, 05:31 PM EST

undefined% (undefined)

Bid	21.61
Market Cap	1.53B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.58
PE Ratio (ttm)	-8.91
Forward PE	n/a
Analyst	Buy

Ask	28.05
Volume	1,061,822
Avg. Volume (20D)	1,042,914
Open	24.68
Previous Close	24.32
Day's Range	22.92 - 24.68
52-Week Range	22.91 - 53.18
Beta	undefined

About CLDX

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 15, 1986

Employees 160

Stock Exchange NASDAQ

Ticker Symbol CLDX

Website https://www.celldex.com

Analyst Forecast

According to 7 analyst ratings, the average rating for CLDX stock is "Buy." The 12-month stock price forecast is $68.5, which is an increase of 197.83% from the latest price.

Buy 57.14%

Hold 42.86%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Celldex Therapeutics Inc. is scheduled to release its earnings on Feb 24, 2025, before market opens.
Analysts project revenue of $1.31M, reflecting a -68.3% YoY shrinking and earnings per share of -0.73, making a -12.05% decrease YoY.

Why Price Moved

3 months ago · Source

-12.06%

Celldex Therapeutics shares are trading lower. The... Unlock content with Pro Subscription

5 months ago · Source

-8.45%

Celldex Therapeutics shares are trading lower. The company announced topline results from its Phase 2 clinical trial of barzolvolimab.

News

2 days ago · https://thefly.com

Blueprint Medicines price target lowered by $11 at Wedbush, here's why

Blueprint Medicines -3.19 (-3.52%) Celldex -2.21 (-8.33%)

2 months ago · zacks.com

Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.81 per share a year ago.

2 months ago · seekingalpha.com

Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market

Celldex's primary revenue driver is Barzolvolimab, now in Phase 3 for CSU, targeting unmet needs in inflammatory diseases. Barzolvolimab has shown strong Phase 2 efficacy for CSU, though safety concer...